Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: inhaled human insulin Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Technosphere Insulin Inhalation Powder, Rapid Acting Analog; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Encino, California • Fresno, California • Oakland, California + 25 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Investigational inhaled insulin (Technosphere), Artificial Pancreas (AP) device (APS©); Drug · Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: pioglitazone, inhaled human insulin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 110
States / cities: Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more

Conditions: Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
Interventions: Inhaled Technosphere Insulin; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more

Conditions: Diabetes Mellitus
Interventions: Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Diabetes Mellitus, Type 1
Interventions: insulin, human insulin inhalation powder (HIIP); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: San Diego, California • Denver, Colorado • Hollywood, Florida + 22 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Subcutaneous Insulin, Inhaled Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 36
States / cities: Fullerton, California • Long Beach, California • Sacramento, California + 31 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Inhaled human insulin (EXUBERA™); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 34
States / cities: Burlingame, California • Irvine, California • Los Angeles, California + 31 more

Conditions: Asthma, Diabetes Mellitus
Interventions: Inhaled Insulin, Subcutaneous Insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 86
States / cities: Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more

Conditions: Dyslipidemia
Interventions: Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 57
States / cities: Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more

Conditions: Diabetes Mellitus
Interventions: Exubera® (inhaled insulin); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 12
States / cities: San Diego, California • New Haven, Connecticut • Miami, Florida + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Educational Materials; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 42
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 36 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Comparator administered in parent trial, Technosphere Insulin Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Fresno, California • Long Beach, California • Atlanta, Georgia + 10 more

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Technosphere Insulin Inhalation Powder, Comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Afrezza plus One Drop | Premium, One Drop | Premium; Drug · Other
Lead sponsor: Informed Data Systems, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more

Conditions: Diabetes Mellitus Type 2
Interventions: Positive Airway Pressure therapy, Lifestyle counseling; Device · Behavioral
Lead sponsor: ResMed; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 11
States / cities: Mission Viejo, California • Temecula, California • Coral Gables, Florida + 8 more

Conditions: Safety and Tolerability
Interventions: inhaled human insulin, Insulin Lispro (Humalog U-100); Drug
Lead sponsor: Dance Biopharm Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Human Insulin Inhalation Powder, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Greenbrae, California • Topeka, Kansas • Toms River, New Jersey + 3 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Control IQ + sleep or exercise activity with TI; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes, Hypertension
Interventions: Yoga lifestyle intervention, Standard of care; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Exubera; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

US Inhaled Insulin Therapeutic Choice Questionnaire Study

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

A 2-Month Safety Follow-Up Trial

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

Yoga for the Management of HIV-Metabolic Syndromes

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes